Stephen A Rosenberg
Overview
Explore the profile of Stephen A Rosenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
930
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fajemisin J, Bryant J, Saghand P, Mills M, Latifi K, Moros E, et al.
JCO Clin Cancer Inform
. 2025 Jan;
9():e2400002.
PMID: 39854670
Purpose: Adaptive radiotherapy accounts for interfractional anatomic changes. We hypothesize that changes in the gross tumor volumes identified during daily scans could be analyzed using delta-radiomics to predict disease progression...
2.
Fajemisin J, Gonzalez G, Rosenberg S, Ullah G, Redler G, Latifi K, et al.
Tomography
. 2024 Sep;
10(9):1439-1454.
PMID: 39330753
Magnetic resonance imaging (MRI) is known for its accurate soft tissue delineation of tumors and normal tissues. This development has significantly impacted the imaging and treatment of cancers. Radiomics is...
3.
Sandoval M, Rishi A, Latifi K, Grass G, Torres-Roca J, Rosenberg S, et al.
Cancer Control
. 2024 Aug;
31:10732748241270595.
PMID: 39206515
Objectives: Stereotactic body radiotherapy (SBRT) is widely used for localized prostate cancer and implementation of MR-guided radiotherapy has the advantage of tighter margins and improved sparing of organs at risk....
4.
Washington I, Palm R, White J, Rosenberg S, Ataya D
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893241
Contrast-enhanced breast MRI has an established role in aiding in the detection, evaluation, and management of breast cancer. This article discusses MRI sequences, the clinical utility of MRI, and how...
5.
Bryant J, Cruz-Chamorro R, Gan A, Liveringhouse C, Weygand J, Nguyen A, et al.
Commun Med (Lond)
. 2024 May;
4(1):96.
PMID: 38778215
Background: Definitive local therapy with stereotactic ablative radiation therapy (SABR) for ultracentral lung lesions is associated with a high risk of toxicity, including treatment related death. Stereotactic MR-guided adaptive radiation...
6.
Bryant J, Madey K, Rosenberg S, Frakes J, Hoffe S
J Cancer Educ
. 2024 May;
39(6):713-720.
PMID: 38761305
Leading successful change efforts first requires assessment of the "before change" environment and culture. At our institution, the radiation oncology (RO) residents follow a longitudinal didactic learning program consisting of...
7.
Naghavi A, Bryant J, Kim Y, Weygand J, Redler G, Sim A, et al.
BMC Cancer
. 2024 Apr;
24(1):437.
PMID: 38594603
Background: Soft tissue sarcomas (STS), have significant inter- and intra-tumoral heterogeneity, with poor response to standard neoadjuvant radiotherapy (RT). Achieving a favorable pathologic response (FPR ≥ 95%) from RT is...
8.
Mills M, Kotecha R, Herrera R, Kutuk T, Fahey M, Wuthrick E, et al.
Clin Transl Radiat Oncol
. 2024 Jan;
45:100719.
PMID: 38292332
Purpose: While dose escalation is associated with improved local control (LC) for adrenal gland metastases (AGMs), the proximity of gastrointestinal (GI) organs-at-risk (OARs) limits the dose that can be safely...
9.
Dudas D, Saghand P, Dilling T, Perez B, Rosenberg S, El Naqa I
Int J Radiat Oncol Biol Phys
. 2023 Dec;
119(3):990-1000.
PMID: 38056778
Purpose: Non-small cell lung cancer (NSCLC) stereotactic body radiation therapy with 50 Gy/5 fractions is sometimes considered controversial, as the nominal biologically effective dose (BED) of 100 Gy is felt...
10.
Liveringhouse C, Netzley A, Bryant J, Linkowski L, Weygand J, Sandoval M, et al.
Adv Radiat Oncol
. 2023 Dec;
8(6):101268.
PMID: 38047218
Purpose: Bladder preservation with trimodal therapy (TMT; maximal tumor resection followed by chemoradiation) is an effective paradigm for select patients with muscle invasive bladder cancer. We report our institutional experience...